Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Détails

Ressource 1Télécharger: BIB_312BEA16C2AD.P001.pdf (2224.76 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_312BEA16C2AD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
Périodique
Clinical Interventions In Aging
Auteur(s)
Poewe W., Antonini A., Zijlmans J.C., Burkhard P.R., Vingerhoets F.
ISSN
1178-1998[electronic], 1176-9092[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
5
Pages
229-238
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Résumé
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson's disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associated with the greatest improvement in motor function. Long-term treatment with LD is, however, often complicated by the development of various types of motor response oscillations over the day, as well as drug-induced dyskinesias. Motor fluctuations can be improved by the addition of drugs such as entacapone or monoamine oxidase inhibitors, which extend the half-life of levodopa or dopamine, respectively. However, dyskinesia control still represents a major challenge. As a result, many neurologists have become cautious when prescribing therapy with LD. This review summarizes the available evidence regarding the use of LD to treat PD and will also address the issue of LD delivery as a critical factor for the drug's propensity to induce motor complications.
Mots-clé
Aged, Antiparkinson Agents/administration & dosage, Antiparkinson Agents/adverse effects, Dyskinesia, Drug-Induced/etiology, Humans, Levodopa/administration & dosage, Levodopa/adverse effects, Parkinson Disease/drug therapy
Pubmed
Web of science
Création de la notice
08/03/2011 12:22
Dernière modification de la notice
20/08/2019 13:16
Données d'usage